Name | Steven Chinn |
---|---|
Institution / Organization / Company | University of Michigan |
Your Office Address | 1500 East Medical Center Drive Ann Arbor, Michigan 48109 United States Map It |
Practice Phone | 734-232-0120 |
Practice Web Site | uofmhealth.org |
Brief Biography/Statement | Dr. Steven Chinn received his medical degree from the Keck School of Medicine at the University of Southern California in 2008, graduating with Senior Honors and elected into the National Alpha Omega Alpha Honor Medical Society. He completed his post-graduate surgical training in Otolaryngology-Head and Neck Surgery at the University of Michigan in 2014 during which he completed an 18-month NIH funded research fellowship in the Molecular Genetics and Cellular Biology of Head and Neck Cancer. He then completed a two-year dual fellowship in Head & Neck Surgical Oncology and Microvascular Reconstructive Surgery at the University of Texas MD Anderson Cancer Center. Dr. Chinn also holds a graduate degree (MPH) in Molecular Epidemiology from the University of Michigan School of Public Health. Dr. Chinn joined the faculty at the University of Michigan in 2016, and currently serves as an Assistant Professor in the Department of Otolaryngology-Head and Neck Surgery. He is a member of the Head and Neck Oncology Division, an active member of the Head and Neck Oncology Translational Research Program, and a member of the University of Michigan Comprehensive Cancer Center. His clinical expertise is in the treatment of all types of head and neck cancer, including minimally invasive robotic surgery and complex oral cancers. He also specializes in complex reconstructive surgery to restore form and function after cancer treatment. His research interests include molecular genetics of oral cavity cancer, head and neck cancer stem cells, the molecular mechanisms of metastasis, and outcomes research with an emphasis on improving survival and functional status. |
Clinical Trials I am enrolling patients into | Randomized Phase II study of DCE-MRI-based dose escalation for poor-prognosis head and neck cancer (Phase II) VISmodegib for ORbital and periocular Basal cell carcinoma (VISORB) (Phase IV) Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy or Radiation Therapy for Locally Advanced Head and Neck Cancer (Phase II) A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands (Phase I) A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies (Phase I) RANDOMIZED PHASE II/III TRIAL OF SURGERY AND POSTOPERATIVE RADIATION DELIVERED WITH CONCURRENT CISPLATIN VERSUS DOCETAXEL VERSUS DOCETAXEL AND CETUXIMAB FOR HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK (Phase II/III) The validation of a novel adherence method for oral oncolytics (N/A) A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (Phase I) RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID (DNA) (Phase II/III) Molecular Analysis for Therapy Choice (MATCH) (Phase II) Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients with HPV+ Oropharyngeal Squamous Cell Cancer (Phase II) Non-Comparative, Open-label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors (Phase I/II) Phase II Investigation of Adjuvant Combined Cisplatin and Radiation with Pembrolizumab in Resected HNSCC (Phase II) Phase II Expansion Trial Evaluating Axitinib in Patients with Unresectable Recurrent, or Metastatic Head and Neck Cancer utilizing Choi Response Criteria (Phase II) An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Phase III) Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Phase II) Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Phase II) Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHN (Phase I/II) An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations (Phase II) A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412) (Phase III) DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS (Phase II) A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy.(Phase II) A Multi-Center open label single arm phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma (Phase II) A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects with Locally Advanced or Metastatic Solid Tumors (Phase I) A MULTI-CENTER PHASE II TRIAL OF INDIVIDUALIZED ADAPTIVE DE-ESCALATED RADIOTHERAPY USING PRE and MID-TREATMENT FDG-PET/CT FOR HPV-RELATED OROPHARYNX CANCER (Phase II) Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (Phase II/III) |
Bibliography |
|